Journals Library


HTA - 16/108/11

Nivolumab for treating metastatic or unresectable urothelial cancer [ID995]

Project title: Nivolumab for treating metastatic or unresectable urothelial cancer [ID995]

Call to action: 16/108 Batch 50

Research type: Evidence Synthesis

Chief investigator: Dr Rob RiemsmaORCID logoorcid.org/0000-0001-8892-0861

Contractor: Kleijnen Systematic Reviews Ltd

Cost: £83,343.75

Started: July 2017 | Status: Project complete

Links to project documentation

The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.

Background & Research Questions

Why the research is being done and what is being asked

Methods

How the research is being done

Publications & Outputs

What the research produced

Outcomes & Impact

What happened as a result of the research

If you would like to receive a notification when this project is updated, please submit your email address below. This will also notify you when the Journals Library report is published.